BridgeMD
Levosimendan in Cardiac Arrest: A Randomized Double-blinded Clinical Phase II Trial (LeICA)
EU CTIS ID: 2024-517279-20-02
What this study is testing
To investigate if a single dose of levosimendan given during cardiopulmonary resuscitation (CPR) for out-of-hospital cardiac arrest (OHCA) increases 30-day survival compared to placebo.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Witnessed OHCA
- Prompt start of CPR (within 2 minutes)
- First recorded rhythm VF or pVT, or PEA in case of suspected pulmonary embolism (as determined by the attending physician)
- Refractory cardiac arrest, i.e. sustained beyond third rhythm check
- Intravenous access
- Age 18-75 years
You likely can't join if
- Traumatic cause of cardiac arrest
- First recorded rhythm asystole
- Time to administration of study drug >30 min after onset of cardiac arrest
- Known or apparent pregnancy
- Known pre-existing severe neurological or systemic disease (e.g. severe dementia, current advanced malignancy, advanced cardiac or pulmonary disease, terminal chronic kidney disease on dialysis)
- Known pre-existing (i.e. current) DNACPR decision
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.